DoD Prostate Cancer Transformative Impact Award | Apply Online

Opportunity Summary:

The DoD Prostate Cancer Transformative Impact Award (Funding Opportunity Number W81XWH-12-PCRP-TIA) is a U.S. Army Medical Research Acquisition Activity (USAMRAA) funding opportunity under the Congressionally Directed Medical Research Programs (CDMRP) that is designed to accelerate prostate cancer research with a clear, near-term and transformative benefit for patients. The program emphasizes work that can meaningfully change patient outcomes in the foreseeable future, rather than early-stage discovery projects that may take many years to reach clinical use. It is positioned within the Military Medical Research and Development CFDA listing (12.420) and falls under the broader category of science, technology, and research and development.

A key feature of this award is that it uses a two-step, invitation-only application process. Applicants must first submit a preproposal, and only those selected will be invited to submit a full application. This structure signals that the sponsor intends to be selective early, focusing full proposal review resources on the most promising, high-impact concepts. The funding instrument is listed as a cooperative agreement and/or grant, which typically indicates the government may have a more active partnership role than in a standard grant (for example, through substantial programmatic involvement, milestones, or coordination expectations), though the exact degree of involvement would be spelled out in the full announcement.

The award is built around a team-science approach. Competitive submissions are expected to be driven by a coordinated research team rather than a single-investigator effort, and the Principal Investigator is expected to have a demonstrated track record of successfully leading large, focused projects. In practice, this usually means the PI should be able to show prior experience managing complex, multidisciplinary programs with clear deliverables, such as multi-site clinical studies, translational pipelines, large consortia, or integrated research programs that move from mechanistic work into patient-facing evaluation. The emphasis is not just on assembling a group of collaborators, but on presenting an integrated plan where each component is aligned to an overarching clinical goal and the team structure supports fast execution.

Because the intent is near-term patient benefit, the required scope must include translational studies, clinical research, and/or clinical trials. This requirement draws a firm line around the kind of work the sponsor wants to fund: research that is already close enough to the clinic to be translated, tested in people, or otherwise directly inform clinical decision-making. Translational studies might include biomarker validation, development of clinically deployable diagnostics, preclinical packages that directly support human testing, or bridging work that moves a therapy or intervention toward clinical readiness. Clinical research could include prospective studies, observational cohorts with actionable endpoints, or comparative effectiveness components, while clinical trials indicate readiness to evaluate an intervention in patients under a formal protocol. The underlying expectation is that the work will not stop at generating scientific insight, but will produce outcomes that can influence patient care, clinical practice, or the therapeutic development pathway on a short timeline.

Another defining requirement is operational readiness: applicants must show they are prepared to initiate the study immediately upon receiving the award, meaning as of the award date. This is a strong signal that the sponsor is looking for projects with critical dependencies already in place, such as established collaborations, clinical and laboratory infrastructure, access to patient populations, trial-ready protocols, preliminary regulatory and ethics planning, and an execution plan that does not rely on long start-up periods. For clinical studies, this may imply that sites and investigators are identified, recruitment pathways are established, and major feasibility risks are already addressed. For translational programs, it suggests that key assays, models, manufacturing plans, or data systems are ready to run without extensive build-out after funding.

From a funding and administrative standpoint, the opportunity was posted March 20, 2012, with an original and current closing date of August 23, 2012, and an archive date of September 22, 2012. The estimated total funding was $19.2 million, with an expected two awards, implying a large, high-investment structure aimed at supporting a small number of ambitious programs. No cost sharing or matching was required. Eligibility is listed as unrestricted, meaning it is broadly open to different types of entities (such as universities, nonprofits, companies, and other organizations), subject to any additional eligibility clarifications that may appear in the full text of the announcement.

For support accessing the full announcement, the listed contact is the CDMRP Help Desk at 301-682-5507.

Browse more opportunities from the same agency: Dept. of the Army USAMRAA

Browse more opportunities from the same category: Science and Technology and other Research and Development

Next opportunity: DoD Prostate Cancer Idea Development Award

Previous opportunity: DoD Prostate Cancer Laboratory Clinical Transition Award

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for W81XWH 12 PCRP TIA

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (W81XWH 12 PCRP TIA) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "W81XWH 12 PCRP TIA", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.